News & Updates

Data presented at the Crohn’s & Colitis Congress (CCC) 2023 reflect the benefit of vedolizumab for inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis), be it alone or in a combination regimen. In one study however, extraintestinal manifestations were observed following vedolizumab use.

Children with Crohn’s disease (CD) are often treated with 5-aminosalicylate (5-ASA) contrary to guidelines, and this practice is associated with a substantial delay in initiating biologic therapy, according to a study presented at this year’s Crohn's & Colitis Congress.

Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.

Isolated hepatitis B core antibody (anti-HBc) positivity appears to increase the risk of liver-related and liver cancer mortality, particularly when accompanied by a high fibrosis score, according to a study of Korean adults.

A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.

Oral supplementation with 1-kestose in patients with mild to moderate ulcerative colitis helps modulate the gut microbiome, which in turn contributes to clinical improvement, as reported in a study.

The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).